STATERA BIOPHARMA INC (STAB) Stock Price & Overview
NASDAQ:STAB • US8575611046
Current stock price
The current stock price of STAB is 0.0911 USD. Today STAB is down by -5.2%. In the past month the price decreased by -20.09%. In the past year, price decreased by -95.38%.
STAB Key Statistics
- Market Cap
- 4.98M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.72
- Dividend Yield
- N/A
STAB Stock Performance
STAB Stock Chart
STAB Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to STAB. When comparing the yearly performance of all stocks, STAB is a bad performer in the overall market: 97.91% of all stocks are doing better.
STAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to STAB. STAB has a bad profitability rating. Also its financial health evaluation is rather negative.
STAB Earnings
STAB Forecast & Estimates
STAB Groups
Sector & Classification
STAB Financial Highlights
Over the last trailing twelve months STAB reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -71.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
STAB Ownership
STAB Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.03 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.53 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About STAB
Company Profile
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).
Company Info
IPO: 2006-07-21
STATERA BIOPHARMA INC
2537 Research Boulevard, Suite 201
Fort Collins COLORADO US
CEO: Christopher Zosh
Employees: 46
Phone: 18886138802.0
STATERA BIOPHARMA INC / STAB FAQ
What does STAB do?
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).
What is the stock price of STATERA BIOPHARMA INC today?
The current stock price of STAB is 0.0911 USD. The price decreased by -5.2% in the last trading session.
What is the dividend status of STATERA BIOPHARMA INC?
STAB does not pay a dividend.
What is the ChartMill rating of STATERA BIOPHARMA INC stock?
STAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of STATERA BIOPHARMA INC (STAB)?
STATERA BIOPHARMA INC (STAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
Can you provide the upcoming earnings date for STATERA BIOPHARMA INC?
STATERA BIOPHARMA INC (STAB) will report earnings on 2023-03-29.